Keros Therapeutics (NASDAQ:KROS) Trading Down 8.9% – Here’s What Happened

Keros Therapeutics, Inc. (NASDAQ:KROS)’s share price was down 8.9% during mid-day trading on Monday . The stock traded as low as $13.07 and last traded at $13.26. Approximately 220,614 shares changed hands during trading, a decline of 72% from the average daily volume of 795,165 shares. The stock had previously closed at $14.56.

Analysts Set New Price Targets

Several brokerages have recently issued reports on KROS. Oppenheimer reduced their price objective on Keros Therapeutics from $102.00 to $63.00 and set an “outperform” rating on the stock in a research report on Monday, December 16th. Scotiabank decreased their price objective on Keros Therapeutics from $77.00 to $44.00 and set a “sector outperform” rating on the stock in a report on Friday, December 13th. Wells Fargo & Company upped their target price on Keros Therapeutics from $88.00 to $111.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Jefferies Financial Group started coverage on Keros Therapeutics in a research note on Tuesday, November 5th. They issued a “buy” rating on the stock. Finally, HC Wainwright dropped their price objective on shares of Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating for the company in a research note on Friday, December 13th. Four investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $75.00.

Keros Therapeutics Trading Down 13.0 %

The business’s 50-day simple moving average is $41.71 and its two-hundred day simple moving average is $48.34. The company has a market capitalization of $512.82 million, a PE ratio of -2.43 and a beta of 1.43.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business had revenue of $0.39 million for the quarter. During the same period in the previous year, the business posted ($1.33) EPS. The firm’s quarterly revenue was up 4750.0% compared to the same quarter last year. On average, analysts forecast that Keros Therapeutics, Inc. will post -5.26 EPS for the current year.

Institutional Investors Weigh In On Keros Therapeutics

A number of institutional investors have recently modified their holdings of KROS. KBC Group NV raised its stake in Keros Therapeutics by 52.0% during the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after buying an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Keros Therapeutics by 26.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after acquiring an additional 280 shares in the last quarter. Values First Advisors Inc. bought a new position in Keros Therapeutics during the third quarter worth $89,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Keros Therapeutics in the second quarter worth $128,000. Finally, LMR Partners LLP bought a new stake in Keros Therapeutics during the third quarter valued at $213,000. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.